PL3484474T3 - Związki fenotiazyny do leczenia zaburzeń rybosomalnych i rybosomopatii - Google Patents
Związki fenotiazyny do leczenia zaburzeń rybosomalnych i rybosomopatiiInfo
- Publication number
- PL3484474T3 PL3484474T3 PL17828436.0T PL17828436T PL3484474T3 PL 3484474 T3 PL3484474 T3 PL 3484474T3 PL 17828436 T PL17828436 T PL 17828436T PL 3484474 T3 PL3484474 T3 PL 3484474T3
- Authority
- PL
- Poland
- Prior art keywords
- ribosomopathies
- treatment
- phenothiazine compounds
- ribosomal disorders
- ribosomal
- Prior art date
Links
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 title 1
- 210000003705 ribosome Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662361631P | 2016-07-13 | 2016-07-13 | |
| PCT/US2017/041851 WO2018013761A1 (en) | 2016-07-13 | 2017-07-13 | Calmodulin inhibitors, chk2 inhibitors and rsk inhibitors for the treatment of ribosomal disorders and ribosomapathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3484474T3 true PL3484474T3 (pl) | 2024-08-26 |
Family
ID=60953391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17828436.0T PL3484474T3 (pl) | 2016-07-13 | 2017-07-13 | Związki fenotiazyny do leczenia zaburzeń rybosomalnych i rybosomopatii |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10980808B2 (pl) |
| EP (2) | EP4427760A3 (pl) |
| JP (1) | JP2019524735A (pl) |
| CN (1) | CN109715158A (pl) |
| AU (2) | AU2017295262B2 (pl) |
| CA (1) | CA3030719A1 (pl) |
| DK (1) | DK3484474T3 (pl) |
| ES (1) | ES2992231T3 (pl) |
| FI (1) | FI3484474T3 (pl) |
| HR (1) | HRP20240902T1 (pl) |
| HU (1) | HUE067075T2 (pl) |
| LT (1) | LT3484474T (pl) |
| MX (2) | MX2019000456A (pl) |
| PL (1) | PL3484474T3 (pl) |
| PT (1) | PT3484474T (pl) |
| SI (1) | SI3484474T1 (pl) |
| WO (1) | WO2018013761A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE067075T2 (hu) * | 2016-07-13 | 2024-09-28 | Childrens Medical Ct Corp | Fenotiazin vegyületek riboszomális rendellenességek és riboszomopátiák kezelésére |
| CA3094481A1 (en) | 2018-04-06 | 2019-10-10 | Camp4 Therapeutics Corporation | Phenothiazine derivatives and uses thereof |
| CN109893529B (zh) * | 2019-03-08 | 2021-04-30 | 中国农业科学院兰州兽医研究所 | 一种pf-4708671在制备预防口蹄疫病毒感染的药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB716230A (en) * | 1953-06-29 | 1954-09-29 | Rhone Poulenc Sa | New phenthiazine derivatives and processes for their preparation |
| FI81498C (fi) | 1987-01-13 | 1990-11-12 | Biocon Oy | Kirurgiska material och instrument. |
| JP2864434B2 (ja) | 1991-01-18 | 1999-03-03 | サイナーゲン，インコーポレーテッド | 腫瘍壊死因子媒介疾患の治療方法 |
| DK0659073T3 (da) | 1992-09-10 | 2002-03-11 | Childrens Medical Center | Bionedbrydelige polymermatrixer med vedvarerende afgivelse af lokalanæstetika |
| WO2003062388A2 (en) * | 2002-01-16 | 2003-07-31 | The Regents Of The University Of California | Inhibition of rna function |
| WO2006086103A2 (en) | 2005-01-10 | 2006-08-17 | University Of Virginia Patent Foundation | Synthesis of inhibitors of p90rsk |
| US20100087474A1 (en) * | 2005-04-27 | 2010-04-08 | University Of Florida | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
| GB0718870D0 (en) * | 2007-09-27 | 2007-11-07 | Univ Dundee | Modulation of RSK |
| EP2348855A4 (en) * | 2008-09-17 | 2013-01-09 | Burnham Inst Medical Research | Small-molecule bonds for stem cell differentiation |
| US9040673B2 (en) | 2009-08-14 | 2015-05-26 | University Of Virginia Patent Foundation | Synthesis and identification of novel RSK-specific inhibitors |
| EP3461482A1 (en) * | 2012-03-16 | 2019-04-03 | Children's Medical Center Corporation | Calcium channel blockers for the treatment of ribosomal disorders and ribosomapathies |
| CA2913583C (en) * | 2012-06-04 | 2019-08-06 | Phoenix Molecular Diagnostics Ltd. | Methods of inhibiting rsk for treatment of breast cancer |
| HUE067075T2 (hu) * | 2016-07-13 | 2024-09-28 | Childrens Medical Ct Corp | Fenotiazin vegyületek riboszomális rendellenességek és riboszomopátiák kezelésére |
| US12215351B2 (en) * | 2017-08-22 | 2025-02-04 | The Children's Medical Center Corporation | Methods for inducing hematopoietic stem cell specificity |
-
2017
- 2017-07-13 HU HUE17828436A patent/HUE067075T2/hu unknown
- 2017-07-13 SI SI201731530T patent/SI3484474T1/sl unknown
- 2017-07-13 LT LTEPPCT/US2017/041851T patent/LT3484474T/lt unknown
- 2017-07-13 WO PCT/US2017/041851 patent/WO2018013761A1/en not_active Ceased
- 2017-07-13 FI FIEP17828436.0T patent/FI3484474T3/fi active
- 2017-07-13 CN CN201780056294.1A patent/CN109715158A/zh active Pending
- 2017-07-13 DK DK17828436.0T patent/DK3484474T3/da active
- 2017-07-13 HR HRP20240902TT patent/HRP20240902T1/hr unknown
- 2017-07-13 ES ES17828436T patent/ES2992231T3/es active Active
- 2017-07-13 EP EP24174240.2A patent/EP4427760A3/en active Pending
- 2017-07-13 PL PL17828436.0T patent/PL3484474T3/pl unknown
- 2017-07-13 AU AU2017295262A patent/AU2017295262B2/en active Active
- 2017-07-13 US US16/315,899 patent/US10980808B2/en active Active
- 2017-07-13 PT PT178284360T patent/PT3484474T/pt unknown
- 2017-07-13 MX MX2019000456A patent/MX2019000456A/es unknown
- 2017-07-13 EP EP17828436.0A patent/EP3484474B1/en active Active
- 2017-07-13 JP JP2019501946A patent/JP2019524735A/ja active Pending
- 2017-07-13 CA CA3030719A patent/CA3030719A1/en active Pending
-
2019
- 2019-01-10 MX MX2022014220A patent/MX2022014220A/es unknown
-
2021
- 2021-02-12 US US17/175,079 patent/US11944625B2/en active Active
-
2023
- 2023-09-22 AU AU2023233195A patent/AU2023233195B2/en active Active
-
2024
- 2024-02-13 US US18/439,926 patent/US20240342173A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4427760A2 (en) | 2024-09-11 |
| CN109715158A (zh) | 2019-05-03 |
| EP3484474B1 (en) | 2024-05-08 |
| CA3030719A1 (en) | 2018-01-18 |
| EP4427760A3 (en) | 2024-11-13 |
| US10980808B2 (en) | 2021-04-20 |
| AU2017295262B2 (en) | 2023-07-06 |
| AU2023233195A1 (en) | 2023-10-12 |
| US20220008420A1 (en) | 2022-01-13 |
| WO2018013761A1 (en) | 2018-01-18 |
| JP2019524735A (ja) | 2019-09-05 |
| LT3484474T (lt) | 2024-07-25 |
| FI3484474T3 (fi) | 2024-07-04 |
| US20190314374A1 (en) | 2019-10-17 |
| HUE067075T2 (hu) | 2024-09-28 |
| AU2023233195B2 (en) | 2025-07-03 |
| MX2019000456A (es) | 2020-01-23 |
| EP3484474A1 (en) | 2019-05-22 |
| HRP20240902T1 (hr) | 2024-10-11 |
| US11944625B2 (en) | 2024-04-02 |
| ES2992231T3 (es) | 2024-12-10 |
| US20240342173A1 (en) | 2024-10-17 |
| SI3484474T1 (sl) | 2025-05-30 |
| EP3484474A4 (en) | 2020-07-22 |
| AU2017295262A1 (en) | 2019-02-28 |
| DK3484474T3 (da) | 2024-06-24 |
| MX2022014220A (es) | 2023-04-14 |
| PT3484474T (pt) | 2024-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| SMT201900172T1 (it) | Ammino triazoli sostituiti utili come inibitori della chitinasi umana | |
| IL258032B (en) | Compounds and preparations for the treatment of ocular disorders | |
| ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
| IL262825A (en) | Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment | |
| IL272097A (en) | Compounds for the prevention and treatment of medical disorders and their uses | |
| GB201401086D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| ZA202002993B (en) | Compounds for the treatment of neuromuscular disorders | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| GB201506654D0 (en) | Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| IL263862A (en) | Mitochondrial inhibitors for the treatment of proliferation disorders | |
| PL3484474T3 (pl) | Związki fenotiazyny do leczenia zaburzeń rybosomalnych i rybosomopatii | |
| IL251135A (en) | A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment | |
| ZA201700037B (en) | Compounds for the treatment of seizures and other central nervous system disorders and conditions | |
| HK40008619B (en) | Phenothiazine compounds for the treatment of ribosomal disorders and ribosomopathies | |
| GB201500555D0 (en) | Method and device for the treatment of diseases | |
| PT3724173T (pt) | Compostos para o tratamento de distúrbios neuromusculares | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders |